Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 15/20 | 1.00 |
| ▸ | CDK4 | P11802 | 9/20 | 1.00 |
| ▸ | CCND1 | P24385 | 9/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.59 |
| ▸ | CCND3 | P30281 | 1/20 | 0.59 |
| ▸ | CDK9 | P50750 | 1/20 | 0.59 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22005395 | 1.00 | CDK2 (1.00) | CDK2CCNE1CDK4CCND1CCNT1 | |
| SCHEMBL15249256 | 1.00 | CDK2 (1.00) | CDK2CCNE1CDK4CCND1CCNT1 | |
| SCHEMBL10082757 | 0.92 | CDK2 (1.00) | CDK2CCNE1CDK4CCND1 | |
| SCHEMBL15249257 | 0.92 | CDK2 (1.00) | CDK2CCNE1CDK4CCND1 | |
| SCHEMBL16074639 | 0.92 | CDK2 (1.00) | CDK2CCNE1CDK4CCND1 | |
| SCHEMBL17850345 | 0.89 | CDK2 (0.81) | CDK2CCNE1CDK4CCND1CCNT1 | |
| SCHEMBL25949792 | 0.89 | CDK2 (0.94) | CDK2CCNE1CDK4CCND1 | |
| SCHEMBL25950183 | 0.89 | CDK2 (0.94) | CDK2CCNE1CDK4CCND1 | |
| SCHEMBL15249253 | 0.88 | CDK2 (0.86) | CDK2CCNE1CDK4CCND1CCNT1 | |
| SCHEMBL18493781 | 0.87 | CDK2 (1.00) | CDK2CCNE1CDK4CCND1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | G1 THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20140275067-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275067-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271466-A1 | HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271466-A1 | HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275066-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275066-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014144326-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144740-A2 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140271460-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014144847-A2 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | CDK2 13/4885CCNE1 72/4885CDK4 2/4885 |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | CDK2 69/4885CCNE1 58/4885CDK4 16/4885 |
| US-20140275067-A1 | Transient Protection of Normal Cells During Chemotherapy | CDK6, CCNC, MCL1 | CDK2 10/4885CCNE1 42/4885CDK4 6/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | CDK2 10/4885CCNE1 42/4885CDK4 6/4885 |
| US-20140271466-A1 | HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation | RB1, CDK4, CDKN1A | CDK2 13/4885CCNE1 72/4885CDK4 2/4885 |
| US-20140271460-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | MKI67, PCNA, HRAS | CDK2 69/4885CCNE1 58/4885CDK4 16/4885 |
| US-20140275066-A1 | Transient Protection of Normal Cells During Chemotherapy | CDK6, CCNC, MCL1 | CDK2 10/4885CCNE1 42/4885CDK4 6/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | CDK2 16/4885CCNE1 75/4885CDK4 1/4885 |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | RB1, CDK4, CDKN1A | CDK2 13/4885CCNE1 72/4885CDK4 2/4885 |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | CDK2 10/4885CCNE1 42/4885CDK4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.